BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
First Claim
1. A T cell activating bispecific antigen binding molecule comprising(a) a first antigen binding moiety which specifically binds to a first antigen;
- (b) a second antigen binding moiety which specifically binds to a second antigen;
wherein the first antigen is an activating T cell antigen and the second antigen is CEA, or the first antigen is CEA and the second antigen is an activating T cell antigen; and
wherein the antigen binding moiety which specifically binds to CEA comprises a heavy chain variable region, particularly a humanized heavy chain variable region, comprising the heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO;
14, the HCDR 2 of SEQ ID NO;
15 and the HCDR 3 of SEQ ID NO;
16, and a light chain variable region, particularly a humanized light chain variable region, comprising the light chain complementarity determining region (LCDR) 1 of SEQ ID NO;
17, the LCDR 2 of SEQ ID NO;
18 and the LCDR 3 of SEQ ID NO;
19.
6 Assignments
0 Petitions
Accused Products
Abstract
The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
-
Citations
58 Claims
-
1. A T cell activating bispecific antigen binding molecule comprising
(a) a first antigen binding moiety which specifically binds to a first antigen; -
(b) a second antigen binding moiety which specifically binds to a second antigen; wherein the first antigen is an activating T cell antigen and the second antigen is CEA, or the first antigen is CEA and the second antigen is an activating T cell antigen; and wherein the antigen binding moiety which specifically binds to CEA comprises a heavy chain variable region, particularly a humanized heavy chain variable region, comprising the heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO;
14, the HCDR 2 of SEQ ID NO;
15 and the HCDR 3 of SEQ ID NO;
16, and a light chain variable region, particularly a humanized light chain variable region, comprising the light chain complementarity determining region (LCDR) 1 of SEQ ID NO;
17, the LCDR 2 of SEQ ID NO;
18 and the LCDR 3 of SEQ ID NO;
19. - View Dependent Claims (2, 4, 6, 7, 8, 9, 12, 13, 20, 22, 23, 24, 26, 29, 32, 34, 36, 37, 38, 39, 41, 42, 45, 46, 47, 50, 52, 53, 54, 55, 56, 58)
-
-
3. (canceled)
-
5. (canceled)
-
10-11. -11. (canceled)
-
14-19. -19. (canceled)
-
21. (canceled)
-
25. (canceled)
-
27-28. -28. (canceled)
-
30-31. -31. (canceled)
-
33. (canceled)
-
35. (canceled)
-
40. (canceled)
-
43-44. -44. (canceled)
-
48-49. -49. (canceled)
-
51. (canceled)
-
57. (canceled)
Specification